GVR Report cover Autologous Cell Therapy Market Size, Share & Trends Report

Autologous Cell Therapy Market Size, Share & Trends Analysis Report By Application (Cancer, Neuro-degenerative Disorder, Cardio-vascular Disorder), By End-use, By Source, By Region, And Segment Forecasts, 2022 To 2030

  • Report ID: GVR453510
  • Number of Pages: 0
  • Format: Electronic (PDF)

Autologous Cell Therapy (ACT) is a novel therapeutic intervention that uses an individual’s cells for in-vitro culture and re-introduction into the body. The global ACT market is set out for major growth due to the rise in the number of people suffering from conditions like neurodegenerative disorders, autoimmune disorders, multiple sclerosis, cancer, and so on. These therapies are also used for niche therapeutic utility such as orthopedics and wound healing. Moreover, the rise in the proportion of the geriatric population across the globe coupled with the demand for regenerative medicine, are positively impacting the market growth.

The therapy is intended to replace unhealthy cells with healthy ones mostly by induced expression or the removal of disease causing or dysfunctional cells using immune cells. Advancements in disease biology, coupled with trending technologies such as cell culture, genetic, and protein engineering are conducive to growth of this market. For instance, in December 2021, researchers at the Columbia University Irving Medical Center found out that gene-based cell therapy for SCD restores blood cells to their normal shape and eliminates clinical complications for at least three years.

ACT offer numerous immunological advantages such as eliminating the possibility of graft-versus-host disease (GvHD), which can cause inflammatory symptoms such as enteritis, and dermatitis. They are preferred to achieve Immuno-compatibility for transplantation and also to rule out the need for immunosuppression. Utility of somatic cells for reprogramming into iPSCs to combat Parkinson’s disease. Many studies are underway for using cell therapy to treat Parkinson’s disease. For instance, in May 2022, Aspen Neuroscience plans to advance its lead candidate for Parkinson’s disease and raised USD 147.5 million in Series B financing.

This therapy is being extensively used for devising novel cancer therapeutics and yielded promising outcomes in many studies carried out by researchers across the globe to curb the proliferation of tumorous growth. For instance, in May 2022, Autolus plc presented its research findings at the American Society of Gene & Cell Therapy (ASGCT) about CAR-T cell therapy to treat cancer by using a versatile constitutive cytokine receptor (CCR) system to leverage T cell therapies and to avoid systemic toxicity. Similarly, in April 2022, Autolus Therapeutics plc declares that the U.S. FDA grants an RMAT (Regenerative-Medicine Advanced Therapy) designation for its CAR-T cell therapy called obecabatagene autoleucel (intended for use in the treatment of acute lymphocytic leukemia) that is now undergoing Phase-II trial.

Advantages include the minimization of risks from bio-incompatibility, and disease transmission risks associated with grafts and are therefore used to bioengineer skin substitutes, aid wound healing, reversal of chronic inflammation, treat ulcers, and leverage postoperative healing. There are many corporate developments in terms of acquisitions and expansions to effectively market wound healing technologies. For instance, in June 2022, Switzerland based company, Healiva acquired two innovative cell therapy assets, EpiDex and Healiva002 from Smith+Nephew so as to establish a broad spectrum of personalized wound care by comprehensive use of enzyme technology, ACT, and associative medical devices.

However, hassles in harvest processes, the logistic intricacies (involving clinical procedures) are hindrances to the growth of the market. It is crucial that the procedures are well-timed and coordinated to mitigate the risk of cross-contamination. Turnaround time of several weeks can make the option not favorable in cases where clinicians are making a last attempt to save the life of a patient.

                                       Autologous Cell Therapy Market Segmentation



By Source

  • Bone Marrow
  • Epidermis
  • Mesenchymal stem cells
  • Haematopoietic stem cells
  • Chondrocytes
  • Others

By Application

  • Cancer
  • Neurodegenerative disorders
  • Cardiovascular disorders
  • Autoimmune disorders
  • Orthopaedics
  • Wound healing
  • Others

By End-Use

  • Hospitals & Clinics
  • Academics & Research
  • Others

By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa


Major companies operating in the market include BrainStorm Cell Therapeutics, Holostem Terapie Avanzate S.R.L, Lineage Cell Therapeutics Inc., Pharmicell Co. Inc, Opexa Therapeutics, Caladrius Biosciences Inc, Castle Creek Biosciences Inc, Regeneus Ltd., Opexa Therapeutics Inc, Takeda Pharmaceutical Company Limited, U.S. Stem Cell Inc, and Vericel Corporation.

gvr icn


gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

gvr icn


We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

esomar icon

ESOMAR certified & member

D&B icon

Leading SME award by D&B

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.

great place to work icon